

Alma Mater Studiorum Università di Bologna
Archivio istituzionale della ricerca

Reduction in antimicrobial resistance prevalence in Escherichia coli from a pig farm following withdrawal of group antimicrobial treatment

This is the final peer-reviewed author's accepted manuscript (postprint) of the following publication:

Published Version:

De Lucia, A., Card, R.M., Duggett, N., Smith, R.P., Davies, R., Cawthraw, S.A., et al. (2021). Reduction in antimicrobial resistance prevalence in Escherichia coli from a pig farm following withdrawal of group antimicrobial treatment. VETERINARY MICROBIOLOGY, 258, 1-8 [10.1016/j.vetmic.2021.109125].

Availability:

This version is available at: <https://hdl.handle.net/11585/821241> since: 2024-11-29

Published:

DOI: <http://doi.org/10.1016/j.vetmic.2021.109125>

Terms of use:

Some rights reserved. The terms and conditions for the reuse of this version of the manuscript are specified in the publishing policy. For all terms of use and more information see the publisher's website.

This item was downloaded from IRIS Università di Bologna (<https://cris.unibo.it/>).
When citing, please refer to the published version.

(Article begins on next page)

1 **Reduction in antimicrobial resistance prevalence in *Escherichia coli* in a pig farm following**
2 **withdrawal of group antibiotic treatment**

3

4 De Lucia A.^{1,2}, Card R.M.², Duggett N.², Smith R.P.³, Davies R.², Cawthraw S.A.², Anjum M.F.²,
5 Rambaldi M.¹, Ostanello F.¹, Martelli F.^{2*}

6

7 ¹*Dipartimento di Scienze Mediche Veterinarie. Università di Bologna. Italy;*

8 ²*Animal and Plant Health Agency (APHA) Bacteriology Department. UK;*

9 ³*Animal and Plant Health Agency (APHA) Department of Epidemiological Sciences. UK*

10

11 Key words: antimicrobial use, antimicrobial resistance, *E. coli*, pig farm, WGS

12

13 ***Corresponding author**

14 current address: Woodham Lane, New Haw, Addlestone, KT15 3NB, United Kingdom.

15

16 E-mail addresses: Alessia.delucia3@studio.unibo.it (A. De Lucia), Roderick.Card@apha.gov.uk
17 (R.M. Card), Nick.Duggett@apha.gov.uk (N.A. Dugget), Richard.P.Smith@apha.gov.uk (R.P.
18 Smith), Rob.Davies@apha.gov.uk (R. Davies), shaun.cawthraw@apha.gov.uk, (S.A.Cawthraw),
19 muna.anjum@apha.gov.uk (M. Anjum), margherita.rambaldi@gmail.com (M. Rambaldi),
20 fabio.ostanello@unibo.it (F. Ostanello), Francesca.Martelli@apha.gov.uk (F. Martelli).

21

22 ¹ Current address: via Tolara di Sopra 50, 40064, Ozzano Emilia, Italy.

23 ^{2,3} Current address: Woodham Lane, New Haw, Addlestone, KT15 3NB, United Kingdom.

24

25 **Highlights**

- 26 • Significant increase in fully susceptible *E. coli* after withdrawal of antibiotics
- 27 • Multidrug resistant *E. coli* decline significantly after withdrawal of antibiotics
- 28 • Resistant commensal *E. coli* remain after withdrawal of antibiotics
- 29 • The environmental reservoir of resistant *E. coli* contributes to persistence in pigs
- 30 • Plasmids have an important role for the maintenance and dissemination of resistance

31

32 **Abstract**

33 An important element in the control of antimicrobial resistance (AMR) is reduction in antimicrobial
34 usage. In the veterinary sector individual antimicrobial treatment of livestock, rather than the use of
35 group treatment, can help achieve this goal. The aim of this study was to investigate how cessation
36 of group antimicrobial treatment impacted the prevalence of AMR in commensal *Escherichia coli* in
37 pigs at one farm over an 11-month period. Minimum inhibitory concentrations of eight antimicrobials
38 were determined for 259 *E. coli* isolates collected during the study. A significant reduction in the
39 prevalence of multidrug resistance and a significant increase in the proportion of full susceptibility to
40 the panel of nine antimicrobials tested was seen after 11 months. Whole genome sequencing of 48
41 multidrug resistant isolates revealed *E. coli* clones that persisted across multiple visits and provided
42 evidence for the presence of plasmids harbouring AMR genes shared across multiple *E. coli* line-
43 ages. *E. coli* were also isolated from on-farm environmental samples. Whole genome sequencing of
44 one multidrug resistant isolate obtained from cleaning tools showed it was clonal to pig-derived *E.*
45 *coli* that persisted on the farm for 11 months. In this study we provide evidence that withdrawal of
46 group antimicrobial use leads to significant reductions in key indicators for AMR prevalence and the
47 importance of the farm environment as a reservoir of resistant bacteria. These findings support policy
48 makers and producers in the implementation of measures to control AMR and reduce antimicrobial
49 use.

50 **1. Introduction**

51 Antimicrobial resistance (AMR) is a naturally occurring phenomenon resulting from the evolutionary
52 adaptation of bacteria (Magnusson et al., 2019; WHO, 2015). The prevalence of AMR in bacteria has
53 increased dramatically over the past few decades, becoming one of the most important threats to
54 global public and animal health (WHO, 2015). One key factor for the emergence, selection, and
55 dissemination of AMR microorganisms in veterinary and human medicine is antibiotic usage
56 (Magnusson et al., 2019). Additionally, in relation to food-producing animals, resistant
57 microorganisms can be introduced onto farms from outside sources such as new stock, vectors
58 including rodents, birds and insects, or through contaminated feed and water (Davies and Wales,
59 2019). Furthermore, AMR bacteria can disseminate resistance genes among the diverse microbial
60 communities via mobile genetic elements, such as plasmids and transposons (Davies and Wales,
61 2019). Commensal bacteria are ubiquitous in the intestinal tract of food-producing animals and are
62 considered good indicators of AMR (EFSA, 2020). In particular, *E. coli* bacteria have been long used
63 as an indicator of faecal pollution and have been chosen as a target bacterial species for AMR
64 surveillance in commensal Gram-negative bacteria from livestock populations (Davies and Wales,
65 2019; EFSA, 2020). In the United Kingdom (UK), data obtained from the AMR-surveillance
66 programme, based on random sampling of the caecal contents of healthy pigs at slaughter in 2017,
67 showed a reduction in the prevalence of *E. coli* resistant to many antimicrobials including ampicillin,
68 gentamicin, sulphonamide, Veterinary Microbiology 258 (2021) 109125 2tetracycline, and
69 trimethoprim (UK-VARSS, 2018). These reductions in AMR parallel a significant decrease in the
70 use of antimicrobials in UK pig herds. Similar studies in other countries, such as Belgium (Callens et
71 al., 2018) and Netherlands (Dorado-García et al., 2016), and in the European Union
72 (ECDC/EFSA/EMA, 2017), have demonstrated associations between reductions in antimicrobial use
73 and AMR in commensal *E. coli*. Importantly, surveillance data are often not collected or structured
74 in a manner that enables a direct correlation between reduced antimicrobial use and decreases in AMR
75 prevalence on individual farms. On-farm longitudinal studies of resistance and antimicrobial usage
76 can link antimicrobial use directly with temporal trends in AMR within herds and the dynamic
77 development and maintenance of resistance. Several farm-based longitudinal studies have helped
78 establish that antimicrobial administration in pigs is associated with an increased prevalence of the
79 corresponding resistance in *E. coli* (Belloc et al., 2005; Lin et al., 2017; Mathew et al., 2003; Varga
80 et al., 2009). Furthermore, following cessation of antimicrobial use, a restoration to pre-treatment
81 levels of the corresponding resistance in *E. coli* has been reported (Belloc et al., 2005; Mathew et al.,
82 2003). An investigation at a single UK pig farm reported a direct link between the cessation of colistin
83 use and the elimination of colistin resistant *E. coli* (Duggett et al., 2018; Randall et al., 2018).

84 However, the broader impact of the cessation of antimicrobial use on AMR in indicator bacteria such
85 as *E. coli* at the farm level remains poorly defined. The aim of this study was to help address this
86 evidence gap by investigating the impact of withdrawal of group antimicrobial treatment on the
87 intestinal carriage of AMR in commensal *E. coli* over a period of 11 months at a UK pig farm. Faecal
88 samples were collected over three time points and processed for quantification of commensal *E. coli*
89 abundance and the abundance of *E. coli* sub-populations resistant to apramycin and trimethoprim-
90 sulfamethoxazole, antimicrobials previously used to treat clinical salmonellosis on the farm.
91 Additionally, *E. coli* were purified by culture from the faecal samples for susceptibility testing against
92 eight antimicrobials, to monitor changes in key outcome indicators such as prevalence of multidrug
93 resistance and full susceptibility. The persistence of *E. coli* clones and presence of plasmids
94 harbouring AMR genes was examined using whole genome sequencing. Finally, isolates were
95 obtained from the farm environment to provide insight to the role of the environment as a reservoir
96 of resistant bacteria that may serve as a source for (re)colonisation of pigs.

97

98 **2. Material and methods**

99 *2.1. Study farm and sampling strategy*

100 This study was carried out on a farrow to finish farm in the UK consisting of approximately 500 sows,
101 2000 weaner and grower pigs, and 2000 finisher pigs. Sows and gilts were housed in outdoor radials
102 and pens, while weaners, growers and finishers were housed in indoor pens. No all-in/all-out
103 programme was operated on the farm, instead a cleaning and disinfection program was performed for
104 empty pens when the pigs were transferred to new accommodation based on age class. *Salmonella*
105 enterica serovar Typhimurium was present on farm at the beginning of the study at a prevalence of
106 approximately 60 % in weaners, resulting in significant clinical disease. For this reason, feed
107 medicated with apramycin (APR) or trimethoprim-sulfamethoxazole (SXT) had been used as group
108 treatment under veterinary advice of weaned pigs when clinical gastrointestinal symptoms occurred,
109 prior to the commencement of this study (Fig. 1). In December 2016 a programme of antimicrobial
110 use reduction was implemented on the farm and antimicrobial group medication was discontinued
111 (antimicrobials were administered individually to treat animals that were clinically sick). The
112 antimicrobial use on this farm was already low (1 mg/kg) compared to the average antimicrobial
113 usage recorded in the pig sector as a whole at this time (131 mg/kg in 2017 and 110 mg/kg in 2018)
114 (UK-VARRS, 2018). After discontinuation of group treatment in weaner pigs, the usage on farm was
115 further reduced, down to 0 mg/kg in the last two quarters of 2018. The farm was followed
116 longitudinally over three visits undertaken at approximately six-month intervals (T1, T2 and T3). The
117 first visit was carried out in May 2017 (T1), the second in September 2017 (T2) and the third in April

118 2018 (T3). On each visit, six pens were randomly selected for each age class of fattening pigs (weaner,
119 grower, and finisher pigs). Five fresh, individual, faecal samples were collected from the floor of each
120 pen (30 samples per age class) and processed at the laboratory within 24 h (see below).

121

122 *2.2. Isolation and enumeration of total E. coli and E. coli recovered on culture plates containing* 123 *apramycin or sulfamethoxazole/trimethoprim in pooled faecal samples*

124 The five individual faecal samples from each pen were pooled (one- gram per sample), resulting in
125 six pools per age group (except for T1 where there were only five pools available). Quantitative
126 bacteriology was performed using the method of Miles et al., 1938 in which a 10-fold dilution series
127 of the pooled faecal samples was prepared in 0.1 M PBS (pH 7.2). The dilutions were plated onto
128 CHROMagar ECC plates for enumeration of total presumptive *E. coli* (i.e. indicator *E. coli*).
129 Dilutions were also plated onto CHROMagar ECC supplemented with either 4 mg/L of trimethoprim-
130 sulfamethoxazole (1:19 ratio) or 32 mg/L of apramycin, to enumerate the *E. coli* sub-populations
131 resistant to these antimicrobials. The EUCAST human clinical breakpoint of resistant > 4 mg/L was
132 used for trimethoprim-sulfamethoxazole to obtain intermediate and clinically resistant isolates
133 (EUCAST, 2021). Apramycin was employed at 32 mg/L to obtain resistant isolates. Presumptive *E.*
134 *coli* were identified by their chromogenic properties and the CFU/g of faeces determined for each
135 pooled sample on selective and non-selective plates. The proportion of presumptive resistant *E. coli*
136 in each pooled sample was then calculated. For each pooled sample one representative presumptive
137 *E. coli* from each antibiotic-containing plate and three presumptive indicator *E. coli* from non-
138 selective plates were sub-cultured to purity. Species identification was verified by MALDI-ToF MS.

139

140 *2.3. Environmental samples*

141 Environmental samples were collected during visit T3. Swab samples of cleaning tools (n = 3) and
142 drinkers (n = 3) were collected from the weaner and grower areas. Swab samples (n = 3) were also
143 collected from a cleaned and disinfected weaner pen (empty at the time of the visit). Individual faecal
144 samples from synanthropic animals (rat, n = 3 and wild bird, n = 3) were also collected at the farm
145 premises. Each environmental sample was placed into 225 mL of Buffered Peptone Water (BPW)
146 and incubated for 18 ± 2 h at 37 ± 1 °C. Following this overnight enrichment a single pool was
147 prepared for each sample type by mixing equal volumes to obtain seven environmental samples from
148 which *E. coli* were isolated by culture as detailed above.

149

150 *2.4. Antimicrobial susceptibility testing*

151 Minimum inhibitory concentrations (MICs) were determined by agar dilution (Andrews, 2001) for
152 the following antimicrobials: ampicillin (AMP), tetracycline (TET), cefotaxime (CTX), florfenicol
153 (FLO), ciprofloxacin (CIP), streptomycin (STR), apramycin (APR) and trimethoprim-
154 sulfamethoxazole (1:5) (SXT). *E. coli* strains ATCC 25922 and NCTC 10418 were used as quality
155 controls. The MIC was recorded as the lowest concentration that prevented visible growth and
156 interpreted using Epidemiological cut-off (ECOFF) values issued by the European Committee on
157 Antimicrobial Susceptibility Testing (EUCAST, 2021). For apramycin no defined ECOFF value or
158 clinical breakpoint for *E. coli* has been published by EUCAST, and the breakpoint of ≥ 32 mg/L
159 proposed by the Danish Integrated Antimicrobial Resistance Monitoring and Research Programme
160 was used (DANMAP, 2004). Isolates were differentiated between susceptible wild type (WT) and
161 non-wild type (NWT) strains based on the ECOFF. When the MIC was above the ECOFF value
162 isolates were defined as being non-wild type (NWT) to the corresponding antimicrobial (Schwarz et
163 al., 2010), and as this does not necessarily correspond to clinical resistance the term ‘reduced
164 susceptibility’ has been used. For subsequent analysis, reduced susceptibility to apramycin and/or
165 streptomycin was scored as reduced susceptibility to the aminoglycoside (AMG) class and multidrug
166 resistance (MDR) was defined as resistance to three or more antimicrobial classes (EFSA, 2020;
167 Schwarz et al., 2010).

168

169 2.5. Whole genome sequence analysis

170 DNA was extracted from fifty MDR *E. coli* isolates using the MagMax core nucleic acid purification
171 kit and the KingFisher flex system (ThermoFisher), according to the manufacturer’s protocol. Whole
172 Genome Sequencing (WGS) was carried out using an Illumina NextSeq or Miseq (2×150 bp).
173 Sequences were deposited in the European Nucleotide Archive (ENA) under study accession number
174 PRJEB39219. AMR gene presence was established using APHA SeqFinder after a quality control
175 step as described previously (Anjum et al., 2016). Raw reads were assembled with SPAdes 3.11
176 (Bankevich et al., 2012) and the assembled genomes were analysed with Abricate
177 (<https://github.com/tseemann/abricate>) to determine presence of AMR genes and plasmid replicon
178 genes on the same contigs. The sequence types (ST) of the isolates were established using MLST
179 (<https://github.com/tseemann/mLst>). A core genome SNP alignment was produced with Snippy
180 (<https://github.com/tseemann/snippy>) using *E. coli* K12 MG1655 (accession: U00096.3) as
181 reference and this was used to build the phylogenetic tree with RAxML (Stamatakis, 2014). The trees
182 were annotated using iTOLv3 (Letunic and Bork, 2016).

183

184 2.6. Statistical analyses

185 Chi-square test was applied for the comparison of the estimated proportion of *E. coli* recovered on
186 antimicrobial plates over time and between age classes. All the CFU counts in pooled faecal samples
187 at specific time points were dichotomized (above or below the median). Temporal trends of AMR
188 and MDR percentages of *E. coli* were analysed using Linear-by-Linear Cochran-Armitage test (Aerts
189 et al., 2011). A Chi-square test was also applied to investigate the percentages of AMR and MDR *E.*
190 *coli* isolates between two different age classes (weaner vs finisher pigs). Statistical analyses were
191 performed using the software SPSS 25.0 (IBM SPSS Statistics, NY, US) and $p < 0.05$ was set as
192 statistically significant.

193

194 **3. Results**

195 The farrow to finisher pig farm was followed for 11-months after the suspension of group
196 antimicrobial treatment (Fig. 1) and a total of 53 pooled pig faecal samples, spanning three time points
197 (T1, T2, and T3) and three age groups (weaner, grower, and finisher) were processed for
198 quantification of *E. coli* abundance and purification of bacterial isolates for susceptibility testing and
199 WGS.

200

201 *3.1. Intestinal carriage of antimicrobial resistant E. coli in pigs differs by age class*

202 Quantitative bacteriology was performed on all pig faecal samples to estimate the abundance of total
203 *E. coli* and the abundance of *E. coli* subpopulations able to grow on the APR- and SXT-containing
204 plates. All samples were positive for growth of indicator *E. coli* and SXT-resistant sub-populations.
205 All samples were also positive for the presence of APR-resistant sub-populations, except four samples
206 from finishers. Indicator *E. coli* were present at an overall geometric mean of 4.7×10^6 CFU/g and
207 the abundance of APR- and SXT-resistant populations had overall geometric means of 4.5×10^5
208 CFU/g and 5.2×10^4 CFU/g respectively (Supplementary Table 1). The proportion of *E. coli* recov-
209 ered from APR- and SXT-containing plates varied between samples, although SXT-resistant *E. coli*
210 were consistently more abundant than the APR-resistant sub-population (Supplementary Fig. 1;
211 Supplementary Table 1). Between-sample variation in abundance was highest in weaner pigs and
212 lowest in finisher pigs (Supplementary Fig. 1). Furthermore, there was a significant difference in the
213 proportion of APR-resistant and STX-resistant *E. coli* between weaners and finishers ($p < 0.001$ and
214 $p = 0.005$ respectively). Although a visual trend for reduced abundance of resistant *E. coli* can be
215 discerned between visits T1 and T3 this was not statistically significant.

216

217 *3.2. The proportion of antimicrobial susceptible E. coli isolates increased in pigs following*
218 *withdrawal of group antimicrobial treatment*

219 To further examine changes in antimicrobial susceptibility, a total of 259 *E. coli* isolates were
220 cultured from the pig faecal samples across the three farm visits: T1 (n = 82), T2 (n = 89), and T3 (n
221 = 88). Isolates were obtained from weaners (n = 85), growers (n = 89), or finishers (n = 85); and
222 comprised indicator *E. coli* (n = 159), and *E. coli* recovered from APR selective plates (n = 48) and
223 from SXT selective plates (n = 52) (Supplementary Table 2). All were verified as *E. coli* by MALDI-
224 ToF and tested by agar dilution for susceptibility towards nine antimicrobials (trimethoprim-
225 sulfamethoxazole in combination). In the 159 indicator *E. coli*, recovered from non-selective agar a
226 high proportion were susceptible to streptomycin (82 %), apramycin (87 %), florfenicol (91 %) and
227 ciprofloxacin (98 %) and all were susceptible to cefotaxime (Fig. 2). A lower proportion had
228 susceptibility to tetracycline (45 %), ampicillin (67 %), and trimethoprim-sulfamethoxazole (67 %).
229 Fifty indicator *E. coli* (31 %) were susceptible to all antimicrobials tested and there was a significant
230 increase in fully susceptible isolates between T1 and T3 (p = 0.001) (Fig. 3A). Additionally, there
231 was a significant increase in the proportion of indicator *E. coli* susceptible to ampicillin (p = 0.01)
232 and trimethoprim-sulfamethoxazole (p = 0.007) between visits T1 and T3 (Fig. 2). A similar
233 increasing temporal trend was also observed for apramycin and streptomycin, but these differences
234 were not statistically significant.

235 All isolates purified from APR- and SXT-containing plates were NWT, showing a reduced
236 susceptibility to these respective compounds, except isolate ADL131 which had an apramycin MIC
237 of 16 mg/L (Supplementary Table 3). Comparing visits T1 and T3, the *E. coli* from selective APR-
238 containing plates showed a significant increase in the proportion of susceptible strains to four
239 antimicrobial agents: ampicillin (p = 0.01), streptomycin (p = 0.02), trimethoprim-sulfamethoxazole
240 (p = 0.03) and tetracycline (p = 0.03) (Fig. 2). A similar increase between T1 and T3 in the
241 subpopulation of *E. coli* from SXT-containing plates was noted for only streptomycin (p = 0.006)
242 (Fig. 2). When examined by pig age class, the proportion of indicator *E. coli* susceptible was higher
243 in finishers compared to weaners for all eight antimicrobials tested; with significant differences for
244 ampicillin, apramycin, florfenicol, SXT, and streptomycin (p < 0.05) (Supplementary Fig. 2). There
245 was no significant change in the proportion of susceptible isolates by age class for *E. coli* obtained
246 from APR-containing plates, however *E. coli* from SXT-containing plates had a significant increase
247 in proportion of susceptible strains to ampicillin (Supplementary Fig. 2).

248

249 3.3. Intestinal carriage of multidrug-resistant *E. coli* in pigs decreased following withdrawal of 250 group antimicrobial treatment

251 Having observed significant reductions in resistance to individual antimicrobials we next examined
252 how withdrawal of group antimicrobial treatment affected multidrug resistance (MDR) in the *E. coli*.

253 For this we defined multidrug resistance as reduced susceptibility to three or more antimicrobial
254 classes. Of the 259 pig-derived *E. coli* isolates 46 % (118/259) were MDR. The proportion of MDR
255 isolates was significantly higher ($p < 0.001$) in *E. coli* from APR-containing plates (69 %) and SXT-
256 containing plates (73 %) compared to the indicator *E. coli* (30 %), which were isolated in the absence
257 of antimicrobials (Supplementary Table 2). When examined by age class the percentage of MDR
258 indicator *E. coli* from weaner pigs was significantly higher ($p < 0.001$) than finisher pigs (Table 1).
259 Furthermore, between visits T1 and T3 there was a significant decrease ($p = 0.023$) in the proportion
260 of MDR *E. coli* isolates (Fig. 3B and Supplementary Table 2). A total of 14 different MDR
261 phenotypes were observed (Supplementary Table 4). The most commonly observed MDR phenotype
262 (48/ 118; 41 %) was resistance to ampicillin, trimethoprim-sulfamethoxazole, tetracycline and
263 aminoglycosides (ASTTeA) (Supplementary Table 4). As a proportion of total *E. coli* there was a
264 significant reduction in isolates with this predominant phenotype between T1 and T3 ($p = 0.005$), but
265 not as a proportion of total MDR isolates ($p = 0.64$).

266

267 3.4. Multidrug resistant *E. coli* are present in the farm environment

268 Environmental samples were collected during the T3 farm visit, as evidence emerged for the
269 persistence of resistance following preliminary observation of results from T1 and T2. This enabled
270 an investigation into the potential role for the farm environment to act as a reservoir of resistant
271 bacteria that may serve as a source for (re)colonisation of pigs. Seven environmental sample types
272 were examined (see methods) and, following overnight enrichment in BPW, they all yielded growth
273 of *E. coli* on antibiotic-free plates and plates containing APR or SXT. A single colony was purified
274 from each plate (total isolates = 21). Two isolates were fully susceptible to the antimicrobials tested,
275 while the remaining 19 isolates were NWT with reduced susceptibility to at least one antimicrobial
276 (Supplementary Table 3). All the environmental *E. coli* obtained from APR-containing plates ($n =$
277 7) and SXT-containing plates ($n = 7$) had reduced susceptibility (i.e. NWT) to apramycin and
278 trimethoprim-sulfamethoxazole respectively (Supplementary Table 3). Twelve of the 21
279 environmental isolates (57 %) had an MDR phenotype (Supplementary Table 3). Isolate ADL629
280 had the ASTTeA phenotypic resistance pattern common in pigs on the farm, and was isolated from
281 farm equipment used for cleaning weaner pens. Additionally, the wild bird sample yielded an *E. coli*
282 isolate (ADL648) with reduced susceptibility to seven of the eight antimicrobials tested (ampicillin,
283 ciprofloxacin, florfenicol, tetracycline, trimethoprim-sulfamethoxazole, streptomycin, and
284 apramycin). Three *E. coli* were obtained from swabs of the empty weaner pen after it had been
285 cleaned and disinfected, of which one (strain ADL636) showed reduced susceptibility to four
286 antimicrobials (ampicillin, trimethoprim-sulfamethoxazole, florfenicol, and apramycin).

288 *3.5. Multidrug resistant E. coli clones are present in both pigs and the farm environment*

289 Forty six of 48 pig-derived *E. coli* with the predominant ASTTeA pattern and the environmental
290 isolates ADL629 (cleaning tool) and ADL648 (wild bird faeces) were subjected to WGS and
291 investigated for their genetic diversity and relationship. There was good correspondence between the
292 AMR phenotype and AMR genes, with all isolates having at least one gene encoding resistance to
293 each component of the MDR pattern (Fig. 4); except isolate ADL171 that had reduced susceptibility
294 to ampicillin but no beta-lactamase AMR gene. Ampicillin resistance was associated with the beta-
295 lactamase genes blaTEM-1b, blaTEM-1 or blaOXA-1. Isolate ADL282 harboured blaTEM-1b and a
296 C to T mutation at position -42 in the chromosomal ampC promoter region, and although resistant to
297 ampicillin was susceptible to cefotaxime. All isolates harboured representatives of the sul and dfrA
298 AMR genes, which confer sulphonamide and trimethoprim resistance respectively. Tetracycline
299 resistance was associated with tetA(B) and tetA(4), with 25/48 isolates harbouring both genes.
300 Streptomycin resistance was conferred by ant3-Ia, strAB, aadA2, aadA12, or aadA24 and apramycin
301 resistance by aac(3)-IVa. WGS also revealed the presence of further AMR genes, which can confer
302 resistance to antimicrobials not in the panel tested in this study. For example, the chloramphenicol
303 AMR genes cml and catA1 were present in 36 and 1 isolate respectively; notably these genes have
304 not been associated with resistance to florfenicol (Stubberfield et al., 2019); two isolates harboured
305 floR (ADL152 and ADL648). Isolates ADL6 and ADL263 harboured mphB, which confers
306 resistance to azithromycin. The aminoglycoside resistance genes aph(3')-Ia, aph(3')-IIa and aph(4)-
307 Ia were present in 28, 24 and 38 isolates respectively, and 14 isolates possessed the streptothricin
308 AMR gene sat2A. Considerable genetic diversity was observed within the 48 examined MDR *E. coli*
309 with a total of 22 different STs identified; ST10 was the most common (13/48; 27 %), and seven
310 isolates had a new MLST (Fig. 4). The maximum likelihood phylogenetic tree based on core genome
311 single nucleotide polymorphisms (SNPs) illustrated this diversity and additionally allowed
312 identification of eight sub-clusters of *E. coli*, which we have called “clones” due to the high sequence
313 similarity in the core genome between members of a clone (≤ 10 SNP difference, in accordance with
314 (Schürch et al., 2018)) (Fig. 4). Seven of the eight clones were present in different age classes and/or
315 at different time points, indicating their persistence on-farm. These included clone 1 (ST10), clone 4
316 (ST165) and clone 5 (ST1112), which were isolated from different age classes and from different
317 time points. Clone 6 (ST2705), clone 7 (ST57) and clone 8 (ST925) were detected in one visit each,
318 but from different age groups. Clone 3 (ST unknown) comprised the environmental isolate ADL629
319 (obtained from a cleaning tool at visit T3) and four isolates from grower pigs (two each at visit T1
320 and T3). The two isolates that comprised clone 2 were detected only in weaner pigs at visit T1. Each

321 clone harboured a different repertoire of AMR genes (Fig. 4). However, all isolates in a single clone
322 harboured the same AMR genes (except for clones 3 and 8, in which a single isolate harboured 4 or
323 1 additional genes respectively). AMR gene carriage in clone 3 was identical between the
324 environmental isolate ADL629 and three of the four pig *E. coli* isolates, each harboured ten AMR
325 genes: aadA2, ant(3'')-Ia, strA, strB, cml, dfrA12, sat2A, sul3, blaTEM-1b and tetA(B) (Fig. 4).
326 Analysis of sequence assemblies provided evidence for linkage between AMR genes and also their
327 co-location with plasmid markers, and four exemplars are presented in Table 1. A contig with an
328 IncHI2 plasmid marker and the AMR genes strA and strB was present in all isolates from clones 1
329 and 4, and five further isolates. The clone 2 isolates both carried a ColRNAI plasmid contig with the
330 AMR genes strA, strB, sul2, and dfrA14. This candidate ColRNAI plasmid was also present in two
331 more *E. coli* of different lineages, although in one isolate (ADL467) the contig was shorter and
332 carried only strB and sul2. A potential IncQ1 plasmid harbouring strA, strB and sul2 was present in
333 three isolates from different lineages. A candidate IncFIA/B plasmid was present in the two clone 3
334 isolates and one additional isolate. Interestingly each of these four plasmid contigs harbouring AMR
335 genes were present at more than one time-point.

336

337 **4. Discussion**

338 In this study we examined if the withdrawal of group antimicrobial treatment results in changes to
339 the occurrence of AMR in commensal *E. coli* of healthy pigs. Quantitative bacteriology showed the
340 persistence of *E. coli* sub-populations resistant to apramycin and trimethoprim-sulfamethoxazole on
341 the farm and no significant reduction in the proportion of resistant isolates over the 11 month study
342 period. Both antimicrobials had been used to treat clinical salmonellosis in weaners on the farm in
343 the period prior to the study. It would have been informative to investigate the impact of this treatment
344 regime on AMR in commensal *E. coli* and establish an earlier AMR baseline, before cessation of
345 group treatment, but unfortunately due to practical restrictions we were not able to collect samples
346 during this preceding period. To provide a greater resolution into the effect of antimicrobial
347 withdrawal we undertook susceptibility testing of 259 *E. coli* isolates purified from the pig faecal
348 samples. Reduced susceptibility to tetracycline, ampicillin, and trimethoprim-sulfamethoxazole was
349 most common, and these antimicrobials have the greatest use in the pig sector (EFSA, 2020; UK-
350 VARSS, 2018), although of these only trimethoprim-sulfamethoxazole had been used recently on this
351 farm. Importantly, amongst the isolates studied, reduced susceptibility towards ciprofloxacin was
352 very low and no isolates were resistant to cefotaxime, as both are highest priority critically important
353 antimicrobials. Examination of isolates by time-point revealed several important changes in AMR
354 prevalence. Of particular note is the significant decrease in the proportion of MDR isolates and

355 significant increase in isolates susceptible to the antimicrobial panel used over the 11 months. These
356 key outcome indicators provide a useful correlation with antimicrobial use and suggest that a change
357 from group to individual treatment is a practicable approach for reducing the burden of AMR in pigs.
358 There was also a significant increase in the proportion of isolates susceptible to ampicillin and
359 trimethoprim-sulfamethoxazole, but not to the other six antimicrobials tested. This highlights the
360 complexity and challenges presented by AMR, with many factors not yet fully elucidated, especially
361 regarding the mechanism of dissemination and maintenance of resistance on farms (Davies and
362 Wales, 2019). Indeed, AMR bacteria may be isolated repeatedly from subsequent groups of animals,
363 even in the face of little external selection pressure and frequent cleaning and disinfection (Davies
364 and Wales, 2019). A longer study period or an increased sampling and testing effort might have
365 helped uncover smaller effects of withdrawal on AMR prevalence. However, power calculations
366 based on our sample size of 53 indicates that there was an approximately 15 % chance that a decrease
367 of 10 % per time point from an initial prevalence ranging from 30% to 50% would be detected as
368 statistically significant. Furthermore, although harbouring AMR provides a clear selective advantage
369 for *E. coli* in the presence of antimicrobials, it may impose little or no selective disadvantage in their
370 absence (Davies and Wales, 2019). Indeed bacterial adaptations such as compensatory mutations and
371 plasmid addiction systems are recognised drivers for the maintenance of AMR in bacterial
372 populations (Davies and Wales, 2019) The farm environment plays a critical role as potential
373 reservoir of resistant microorganisms that can re-colonise livestock after the cessation of
374 antimicrobial use (Davies and Wales, 2019). Farm biosecurity (e. g. controlling access by wildlife)
375 and effective cleaning and disinfection are therefore important tools in the control of AMR (Davies
376 and Wales, 2019; Magnusson et al., 2019; WHO, 2015). The farm involved in this study did not
377 employ an all-in/all out management system but did have a generally good routine of cleaning and
378 disinfection after depopulation of the pig pens. However, in the weaner building cleaning and
379 disinfection was done on a pen basis and there was the potential for seepage of contaminated material
380 through poorly fitting wooden panels to adjacent pens. Environmental sampling at this farm
381 demonstrated the presence of AMR *E. coli* not only in recently cleaned and disinfected pens, but also
382 on cleaning tools, drinkers, and in wildlife faeces collected from animal pens. During this study we
383 provided advice on good management practices such as all-in/all-out, pen segregation using concrete
384 walls, effective biosecurity measures, and pest control to help minimize the spread of pathogens (such
385 as Salmonella) and AMR bacteria. Implementation of similar interventions would be applicable more
386 broadly to all pig farms (Davies and Wales, 2019; Magnusson et al., 2019). This study highlighted
387 the importance of the environment and good biosecurity through the analysis of the WGS data, which
388 showed that an *E. coli* clone harbouring ten AMR genes (clone 3; Fig. 4) was present on cleaning

389 tools and in pigs at the beginning and end of the 11 month study. Even though the sequencing effort
390 was small (n = 46 isolates from pigs), we identified three more *E. coli* clones (each with a different
391 ST; Fig. 4) that were present in pigs at more than one time point, illustrating the persistence of AMR
392 on farms even when antimicrobial use is very low. Indeed, Birkegård et al., 2017 suggest that
393 antimicrobial exposure is not the only important determinant of AMR gene levels. We have
394 previously demonstrated the persistence of AMR *E. coli* in humans (Card et al., 2015; Kirchner et
395 al., 2014) and this finding in pigs was not unexpected. It is possible that clones circulated in pigs and
396 repeatedly contaminated the environment, leading to transfer between batches. These persistent
397 clones may be well adapted to survival in the pig gut and be spread between animals via direct contact,
398 fomites, or wildlife vectors (Ahmed et al., 2017; Davies and Wales, 2019). The antimicrobial
399 resistance genes found in the isolates examined by WGS have been commonly reported in similar
400 studies on resistance genes in *E. coli* isolates from pigs in Canada, Denmark and UK (AbuOun et al.,
401 2020; Ahmed et al., 2017; Boerlin et al., 2005; DANMAP, 2018; Gerzova et al., 2015). Whole
402 genome sequencing also showed that AMR genes were often linked and potentially located on
403 plasmids, such as the putative ColRNAI plasmid that harboured trimethoprim, sulphonamide, and
404 streptomycin resistance genes (Table 1). Linkage of AMR genes may have contributed to the
405 significantly higher proportions of MDR *E. coli* obtained from APR- and SXT-containing plates.
406 The four exemplar putative plasmids harbouring AMR genes possessed Incompatibility types
407 previously described in Enterobacteriaceae (AbuOun et al., 2020; Ahmed et al., 2017) and each was
408 present in two or more different *E. coli* lineages and persisted across multiple visits to the farm. This
409 provides further evidence that plasmids present a mechanism for the maintenance and dissemination
410 of resistance in the commensal *E. coli* population, especially given the small sequencing effort
411 employed in this project. In future, the use of long read sequencing would provide valuable additional
412 insight into plasmid structure, maintenance, and changes over time (Duggett et al., 2018). Overall,
413 examination of resistance by age class showed that weaners harboured greater proportions of resistant
414 *E. coli* than finishers. Finisher pigs had significantly fewer APR- and SXT-resistant *E. coli*
415 determined by quantitative bacteriology; significantly less *E. coli* isolates with reduced susceptibility
416 (i.e. NWT) towards ampicillin, apramycin, florfenicol, trimethoprim-sulfamethoxazole, and
417 streptomycin; and significantly less MDR *E. coli*. Weaner pigs were housed in pens where individual
418 animals were previously treated with antimicrobials and, as noted above, faced a potential for cross-
419 contamination between pens. In contrast finisher pigs were housed in pens where antimicrobials had
420 not been used. The prevalence of resistant *E. coli* is often higher in young animals because they are
421 more prone to enteric disease and stressed by weaning and mixing with other litters and thus more
422 likely to be treated with antimicrobials (Akwar et al., 2008). Our findings regarding the association

423 of age class with resistance prevalence correlate with previous studies (Akwar et al., 2008) and help
424 inform risk models assessing the potential transfer of resistance to humans via the food chain. In
425 conclusion, although antimicrobial use is strongly associated with an increased abundance of
426 commensal AMR bacteria in humans (Card et al., 2015; Kirchner et al., 2014) and animals (EFSA,
427 2020), few studies have examined the impact of reduced antimicrobial use on AMR prevalence at the
428 farm level. A core objective of the Global Action Plan on AMR is the prudent and efficient use of
429 antimicrobials in public and veterinary medicine (WHO, 2015). To promote responsible antimicrobial
430 use in the livestock sector the FAO recommends individual antimicrobial treatment of pigs, based on
431 a diagnosis of disease, over the use of group treatment (Magnusson et al., 2019). In this study, we
432 provide strong evidence that implementation of these recommendations can lead to significant
433 reductions in key indicators for AMR prevalence, although some residual level of AMR was found
434 to remain. Our findings therefore provide evidence which may assist producers and policy makers in
435 the implementation of Action Plans on AMR. In future it would be informative to undertake a
436 detailed, longer term, economic cost/benefit analysis, encompassing the cost of farm inputs and
437 income obtained, as well as capturing any adverse effects, to further support the implementation of
438 these treatment practices.

439

440 **Declaration of Competing Interest**

441 The authors report no declarations of interest.

442

443 **Acknowledgements**

444 This work was supported by the UK Veterinary Medicine Directorate under Projects VM0533D and
445 VM0533B. One Health European Joint project ARDIG also supported this work. ND, RPS, RD, SAC,
446 MFA and FM were funded by the UK Veterinary Medicine Directorate and funding from the UK
447 Department for Environment, Food & Rural Affairs. FO, MR and ADL were funded by funding from
448 the Department of Veterinary Medical Sciences, Bologna University, Italy and by the Italian Society
449 of Pig Pathology (SIPAS). RMC was supported by the UK FAO Reference Centre for Antimicrobial
450 Resistance (which receives funding from the Department for Environment, Food & Rural Affairs and
451 UK aid funding from the Department of Health and Social Care's Fleming Fund). The Authors wish
452 to thank the farmer and the private veterinarian of the farm visited in this study for their assistance
453 with access to and information about the premise. The Authors wish to thank the APHA Central
454 Sequencing Unit for the whole genome sequencing of isolates.

455

456 **Appendix A. Supplementary data**

457 Supplementary material related to this article can be found, in the online version, at
458 doi:<https://doi.org/10.1016/j.vetmic.2021.109125>.

459

460 **References**

- 461 AbuOun, M., O'Connor, H.M., Stubberfield, E.J., Nunez-Garcia, J., Sayers, E., Crook, D. W., Smith,
462 R.P., Anjum, M.F., 2020. Characterizing antimicrobial resistant *Escherichia coli* and associated
463 risk factors in a cross-sectional study of pig farms in Great Britain. *Front. Microbiol.* 11.
- 464 Aerts, M., Faes, C., Nysen, R., 2011. Development of statistical methods for the evaluation of data
465 on antimicrobial resistance in bacterial isolates from animals and food. *EFSA Support. Publ.* 8,
466 186E.
- 467 Ahmed, S., Olsen, J.E., Herrero-Fresno, A., 2017. The genetic diversity of commensal *Escherichia*
468 *coli* strains isolated from non-antimicrobial treated pigs varies according to age group. *PLoS One*
469 12, e0178623.
- 470 Akwar, H.T., Poppe, C., Wilson, J., Reid-Smith, R.J., Dyck, M., Waddington, J., Shang, D., McEwen,
471 S.A., 2008. Prevalence and patterns of antimicrobial resistance of fecal *Escherichia coli* among
472 pigs on 47 farrow-to-finish farms with different in-feed medication policies in Ontario and British
473 Columbia. *Can. J. Vet. Res.* 72, 195.
- 474 Andrews, J.M., 2001. Determination of minimum inhibitory concentrations. *J. Antimicrob.*
475 *Chemother.* 48, 5–16.
- 476 Anjum, M.F., Duggett, N.A., AbuOun, M., Randall, L., Nunez-Garcia, J., Ellis, R.J., Rogers, J.,
477 Horton, R., Brena, C., Williamson, S., 2016. Colistin resistance in *Salmonella* and *Escherichia coli*
478 isolates from a pig farm in Great Britain. *J. Antimicrob. Chemother.* 71, 2306–2313.
- 479 Bankevich, A., Nurk, S., Antipov, D., Gurevich, A.A., Dvorkin, M., Kulikov, A.S., Lesin, V. M.,
480 Nikolenko, S.I., Pham, S., Prjibelski, A.D., 2012. SPAdes: a new genome assembly algorithm and
481 its applications to single-cell sequencing. *J. Comput. Biol.* 19, 455–477.
- 482 Belloc, C., Lam, D., Pellerin, J.L., Beaudreau, F., Laval, A., 2005. Effect of quinolone treatment on
483 selection and persistence of quinolone-resistant *Escherichia coli* in swine faecal flora. *J. Appl.*
484 *Microbiol.* 99, 954–959.
- 485 Birkegård, A.C., Halasa, T., Græsbøll, K., Clasen, J., Folkesson, A., Toft, N., 2017. Association
486 between selected antimicrobial resistance genes and antimicrobial exposure in Danish pig farms.
487 *Sci. Rep.* 7, 1–8.
- 488 Boerlin, P., Travis, R., Gyles, C.L., Reid-Smith, R., Lim, N.J.H., Nicholson, V., McEwen, S. A.,
489 Friendship, R., Archambault, M., 2005. Antimicrobial resistance and virulence genes of
490 *Escherichia coli* isolates from swine in Ontario. *Appl. Environ. Microbiol.* 71, 6753–6761.

491 Callens, B., Cargnel, M., Sarrazin, S., Dewulf, J., Hoet, B., Vermeersch, K., Wattiau, P., Welby, S.,
492 2018. Associations between a decreased veterinary antimicrobial use and resistance in commensal
493 *Escherichia coli* from Belgian livestock species (2011–2015). *Prev. Vet. Med.* 157, 50–58.

494 Card, R.M., Mafura, M., Hunt, T., Kirchner, M., Weile, J., Rashid, M.-U., Weintraub, A., Nord, C.E.,
495 Anjum, M.F., 2015. Impact of ciprofloxacin and clindamycin administration on Gram-negative
496 bacteria isolated from healthy volunteers and characterization of the resistance genes they harbor.
497 *Antimicrob. Agents Chemother.* 59, 4410–4416.

498 DANMAP, 2004. Use of Antimicrobial Agents and Occurrence of Antimicrobial Resistance in
499 Bacteria from Food Animals, Foods and Humans in Denmark.

500 DANMAP, 2018. Use of Antimicrobial Agents and Occurrence of Antimicrobial Resistance in
501 Bacteria from Food Animals, Food and Humans in Denmark.

502 Davies, R., Wales, A., 2019. Antimicrobial resistance on farms: a review including biosecurity and
503 the potential role of disinfectants in resistance selection. *Compr. Rev. Food Sci. Food Saf.* 18,
504 753–774.

505 Dorado-García, A., Mevius, D.J., Jacobs, J.J., Van Geijlswijk, I.M., Mouton, J.W., Wagenaar, J.A.,
506 Heederik, D.J., 2016. Quantitative assessment of antimicrobial resistance in livestock during the
507 course of a nationwide antimicrobial use reduction in the Netherlands. *J. Antimicrob. Chemother.*
508 71, 3607–3619.

509 Duggett, N.A., Randall, L.P., Horton, R.A., Lemma, F., Kirchner, M., Nunez-Garcia, J., Brena, C.,
510 Williamson, S.M., Teale, C., Anjum, M.F., 2018. Molecular epidemiology of isolates with
511 multiple *mcr* plasmids from a pig farm in Great Britain: the effects of colistin withdrawal in the
512 short and long term. *J. Antimicrob. Chemother.* 73, 3025–3033. ECDC/EFSA/EMA, 2017.

513 ECDC/EFSA/EMA second joint report on the integrated analysis of the consumption of antimicrobial
514 agents and occurrence of antimicrobial resistance in bacteria from humans and food-producing
515 animals: Joint Interagency Antimicrobial Consumption and Resistance Analysis (JIACRA)
516 Report. *EFSA J.* 15, e04872.

517 EFSA, 2020. The European Union Summary Report on Antimicrobial Resistance in zoonotic and
518 indicator bacteria from humans, animals and food in 2017/2018. *EFSA J.* 18, e06007.

519 EUCAST, 2021. European Committee on Antimicrobial Susceptibility Testing (EUCAST)
520 (EUCAST Clinical breakpoints). Gerzova, L., Babak, V., Sedlar, K., Faldynova, M., Videnska, P.,
521 Cejkova, D., Jensen, A.N., Denis, M., Kerouanton, A., Ricci, A., 2015. Characterization of
522 antibiotic resistance gene abundance and microbiota composition in feces of organic and
523 conventional pigs from four EU countries. *PLoS One* 10, e0132892.

524 Kirchner, M., Mafura, M., Hunt, T., Abu-Oun, M., Nunez-Garcia, J., Hu, Y., Weile, J., Coates, A.,
525 Card, R., Anjum, M.F., 2014. Antimicrobial resistance characteristics and fitness of Gram-
526 negative fecal bacteria from volunteers treated with minocycline or amoxicillin. *Front. Microbiol.*
527 5, 722.

528 Letunic, I., Bork, P., 2016. Interactive tree of life (iTOL) v3: an online tool for the display and
529 annotation of phylogenetic and other trees. *Nucleic Acids Res.* 44, W242–W245.

530 Lin, D., Chen, K., Xie, M., Ye, L., Chan, E.W.-C., Chen, S., 2017. Effect of ceftiofur and enrofloxacin
531 on *E. coli* sub-population in pig gastrointestinal tract. *J. Glob. Antimicrob. Resist.* 10, 126–130.

532 Magnusson, U., Sternberg, S., Eklund, G., Rozstalnyy, A., 2019. Prudent and efficient use of
533 antimicrobials in pigs and poultry. *FAO Animal Production and Health Manual*. FAO, Rome, Italy.

534 Mathew, A.G., Arnett, D.B., Cullen, P., Ebner, P.D., 2003. Characterization of resistance patterns
535 and detection of apramycin resistance genes in *Escherichia coli* isolated from swine exposed to
536 various environmental conditions. *Int. J. Food Microbiol.* 89, 11–20.

537 Miles, A.A., Misra, S., Irwin, J., 1938. The estimation of the bactericidal power of the blood.
538 *Epidemiol. Infect.* 38, 732–749.

539 Randall, L., Horton, R., Lemma, F., Martelli, F., Duggett, N., Smith, R., Kirchner, M., Ellis, R.,
540 Rogers, J., Williamson, S., 2018. Longitudinal study on the occurrence in pigs of colistin-resistant
541 *Escherichia coli* carrying *mcr-1* following the cessation of use of colistin. *J. Appl. Microbiol.* 125,
542 596–608.

543 Schürch, A., Arredondo-Alonso, S., Willems, R., Goering, R.V., 2018. Whole genome sequencing
544 options for bacterial strain typing and epidemiologic analysis based on single nucleotide
545 polymorphism versus gene-by-gene-based approaches. *Clin. Microbiol. Infect.* 24, 350–354.

546 Schwarz, S., Silley, P., Simjee, S., Woodford, N., van Duijkeren, E., Johnson, A.P., Gaastra, W.,
547 2010. Assessing the antimicrobial susceptibility of bacteria obtained from animals. *J. Antimicrob.*
548 *Chemother.* 65, 601–604. Stamatakis, A., 2014. RAxML version 8: a tool for phylogenetic analysis
549 and post-analysis of large phylogenies. *Bioinformatics* 30, 1312–1313.

550 Stubberfield, E., AbuOun, M., Sayers, E., O'Connor, H.M., Card, R.M., Anjum, M.F., 2019. Use of
551 whole genome sequencing of commensal *Escherichia coli* in pigs for antimicrobial resistance
552 surveillance, United Kingdom, 2018. *Eurosurveillance* 24. UK-VARSS, 2018. UK Veterinary
553 Antibiotic Resistance & Sales Surveillance.

554 Varga, C., Rajić, A., McFall, M.E., Reid-Smith, R.J., Deckert, A.E., Checkley, S.L., McEwen, S.A.,
555 2009. Associations between reported on-farm antimicrobial use practices and observed
556 antimicrobial resistance in generic fecal *Escherichia coli* isolated from Alberta finishing swine
557 farms. *Prev. Vet. Med.* 88, 185–192.

558 WHO, 2015. Global Action Plan on Antimicrobial Resistance. World Health Organization, Geneva.

559

560

Fig. 1. Farm history and experimental design. Graphic timeline of the administration and withdrawal of antimicrobials and schedule of the sampling visits on-farm over the 11 months of the study period.




Fig. 2. Proportion of wild type (WT) and non-wild-type (NWT) *E. coli* isolates at farm visits T1, T2, and T3. Antimicrobials tested were ampicillin (AMP), tetracycline (TET), cefotaxime (CTX), florfenicol (FLO), ciprofloxacin (CIP), streptomycin (STR), apramycin (APR) and trimethoprim-sulfamethoxazole (SXT). Interpretative criteria to define reduced susceptibility are shown. Significant differences between visits T1 and T3 were determined using Linear-by-Linear. Cochran-Armitage test; * indicate respectively $p < 0.05$




Fig. 3. Proportion of A) fully susceptible indicator *E. coli* and B) total of Multidrug Resistant *E. coli* isolates at farm visits T1 and T3. Full susceptibility was defined as susceptibility to all nine antimicrobials tested and multidrug resistance was defined as resistance to three or more antimicrobial classes; * and ** indicate respectively $p < 0.05$ and $p < 0.001$ respectively.




Table 1. Summary of four different candidate plasmids detected in assemble whole genome sequences that harboured AMR genes and were present in multiple *E. coli* lineages and time points. Where relevant *E. coli* clones is indicated (n/a = isolated not assigned to a clone).

Plasmid incompatibility type	Linked AMR genes	<i>E. coli</i> clone	<i>E. coli</i> ST	Isolate ID	Plasmid contig size (bp)	Visit
IncHI2	<i>strA; strB</i>	1	10	ADL21	109,551	1
		1	10	ADL26	109,755	1
		1	10	ADL56	109,555	1
		1	10	ADL86	109,755	1
		1	10	ADL216	109,551	1
		1	10	ADL221	109,551	1
		1	10	ADL276	109,552	2
		1	10	ADL278	109,552	2
		4	165	ADL302	100,023	2
		4	165	ADL519	99,865	3
		5	1112	ADL41	108,510	1
		n/a	10	ADL490	97,758	3
		n/a	34	ADL282	109,555	2
		n/a	398	ADL101	109,555	1
n/a	683	ADL306	89,493	2		
ColRNAI	<i>strA; strB; sul2; dfrA14</i>	2	10	ADL33	6,951	1
		2	10	ADL63	6,895	1
		n/a	48	ADL272	6,895	2
	<i>strB; sul2</i>	n/a	540	ADL467	4,740	2
IncFIA/B	<i>bla</i> _{TEM-1b}	3	new	ADL137	1,943	2
		3	new	ADL629	2,183	3
		n/a	new	ADL478	1,947	3
IncQ1	<i>strA; strB; sul2</i>	n/a	345	ADL360	4,638	2
		n/a	130	ADL648	4,640	2
		n/a	88	ADL62	4,639	1

Supplementary Table 1. Bacterial counts of presumptive *E. coli* isolated from different pig age classes, recovered from CHROMagar ECC with and without apramycin and sulfamethoxazole/trimethoprim. Number of samples collected per visit and per age classes during each visit are shown in brackets.

Age class	CHROMagar	Farm visit (no. of samples)		
		T1 (17)	T2 (18)	T3 (18)
Weaners (6)	ECC ^a	5.1×10^6	1.5×10^7	8.4×10^6
	SXT ^b	6.4×10^5	2.7×10^6	8.8×10^5
	APR ^c	2.7×10^5	1.7×10^6	2.7×10^5
Growers (6)	ECC	3.6×10^6	5.3×10^7	2.2×10^6
	SXT	6.6×10^5	4.9×10^6	2.8×10^5
	APR	3.0×10^5	2.3×10^6	5.5×10^4
Finishers (6)	ECC	2.3×10^5	1.7×10^7	9.8×10^5
	SXT	1.3×10^4	1.3×10^6	3.6×10^4
	APR	2.5×10^2	2.3×10^4	1.4×10^2
Total	ECC	-	4.7×10^6	-
	SXT	-	4.5×10^5	-
	APR	-	5.2×10^4	-

^a ECC. CHROMagar ECC

^b STX. CHROMagar ECC + 4 mg/L of trimethoprim-sulfamethoxazole (1:19)

^c APR. CHROMagar ECC + 4 mg/L of 32 mg/L of apramycin

Supplementary Table 2: Commensal *E. coli* isolates obtained by culture in the presence or absence of antimicrobials. Data is presented grouped by age-class and by isolate susceptibility: fully susceptible, reduced susceptibility to 1 or 2 antimicrobial classes, and multidrug resistance (reduced susceptibility to ≥ 3 antimicrobial classes). The asterisk (*) indicated significant difference ($p < 0.05$) in the frequency of MDR *E. coli* isolated from finisher and weaner pigs

<i>E. coli</i> population class	Age class	All sensitive				1 or 2 Abs				MDR class			
		T1 (51)	T2 (54)	T3 (54)	T1+T2+T3 (159)	T1 (51)	T2 (54)	T3 (54)	T1+T2+T3 (159)	T1 (51)	T2 (54)	T3 (54)	T1+T2+T3 (159)
Indicator	Weaners	3 (20%)	5 (27,8%)	4 (22,2%)	12 (23,5%)	4 (26,7%)	6 (33,3%)	6 (33,3%)	16 (31,4%)	8 (53,3%)	7 (38,9%)	8 (44,4%)	23 (45,1%)*
	Growers	1 (5,6%)	9 (50%)	7 (38,9%)	17 (31,5%)	9 (50%)	4 (22,2%)	7 (38,9%)	20 (37%)	8 (44,4%)	5 (27,8%)	4 (22,2%)	17 (31,5%)
	Finishers	2 (11,1%)	10 (55,6%)	9 (50%)	21 (38,9%)	12 (66,7%)	7 (38,9%)	7 (38,9%)	26 (48,1%)	4 (22,2%)	1 (5,6%)	2 (11,1%)	7 (13%)*
	Tot Age class	6 (11,8%)*	24 (44,4%)	20 (37%)*	50 (31,4%)	25 (49%)	17 (31,5%)	20 (37%)	62 (39%)	20 (39,2%)	13 (24,1%)	14 (25,9%)	47 (29,6%)
APR-containing plates		T1 (15)	T2 (17)	T3 (16)	T1+T2+T3 (48)	T1 (15)	T2 (17)	T3 (16)	T1+T2+T3 (48)	T1 (15)	T2 (17)	T3 (16)	T1+T2+T3 (48)
	Weaners	0	0	0	0	0	0	4 (66,7%)	4 (23,5%)	5 (100%)	6 (100%)	2 (33,3%)	13 (76,5%)
	Growers	1 (16,7%)	0	0	1 (5,9%)	1 (16,7%)	2 (40%)	2 (33,3%)	5 (29,4%)	4 (66,7%)	3 (60%)	4 (66,7%)	11 (64,7%)
	Finishers	0	0	0	0	0	3 (50%)	2 (50%)	5 (35,7%)	4 (100%)	3 (50%)	2 (50%)	9 (64,3%)
	Tot Age class	1 (6,7%)	0	0	1 (2,1%)	1 (6,7%)	5 (29,4%)	8 (50%)	14 (29,2%)	13 (86,7%)	12 (70,6%)	8 (50%)	33 (68,8%)
SXT-containing plates		T1 (16)	T2 (18)	T2 (18)	T1+T2+T3 (52)	T1 (16)	T2 (18)	T2 (18)	T1+T2+T3 (52)	T1 (16)	T2 (18)	T2 (18)	T1+T2+T3 (52)
	Weaners	0	0	0	0	0	2 (33,3%)	1 (16,7%)	3 (17,6%)	5 (100%)	4 (66,7%)	5 (83,3%)	14 (82,4%)
	Growers	0	0	0	0	2 (33,3%)	1 (16,7%)	2 (33,3%)	5 (27,8%)	4 (66,7%)	5 (83,3%)	4 (66,7%)	13 (72,2%)
	Finishers	0	0	0	0	1 (20%)	2 (33,3%)	3 (50%)	6 (35,3%)	4 (80%)	4 (66,7%)	3 (50%)	11 (64,7%)
	Tot Age class	0	0	0	0	3 (18,8%)	5 (27,8%)	6 (33,3%)	14 (26,9%)	13 (81,3%)	13 (72,2%)	12 (66,7%)	38 (73,1%)

Supplementary Table 4: Frequencies of the most common multidrug-resistant (resistance to ≥ 3 antimicrobial classes) patterns among the 259 *E. coli* commensal isolates tested.

Reduced susceptibility profile	T1		T2		T3	
AMP/SXT/CIP/FLO/TET/AMINO	4	8.7%	1	2.6%	1	2.9%
AMP/SXT/FLO/TET/AMINO	5	10.9%	3	7.9%	0	0.0%
AMP/SXT/CIP/FLO/AMINO	0	0.0%	1	2.6%	0	0.0%
AMP/SXT/TET/AMINO	22	47.8%	17	44.7%	9	26.5%
AMP/FLO/TET/AMINO	1	2.2%	0	0.0%	0	0.0%
AMP/SXT/FLO/AMINO	0	0.0%	1	2.6%	0	0.0%
AMP/SXT/FLO/TET	0	0.0%	2	5.3%	6	17.6%
AMP/SXT/CIP/TET	0	0.0%	1	2.6%	0	0.0%
AMP/CIP/TET/AMINO	0	0.0%	1	2.6%	0	0.0%
AMP/SXT/TET/	5	10.9%	2	5.3%	7	20.6%
AMP/SXT/AMINO	5	10.9%	2	5.3%	3	8.8%
AMP/TET/AMINO	2	4.3%	1	2.6%	4	11.8%
SXT/TET/AMINO	2	4.3%	6	15.8%	4	11.8%
AMP/FLO/TET	0	0.0%	0	0.0%	0	0.0%
Total of MDR*	46	56.1%	38	42.7%	34	38.6%

Antimicrobial tested: Ampicillin (AMP), tetracycline (TET), cefotaxime (CTX), florfenicol (FLO), ciprofloxacin (CIP), trimethoprim-sulfamethoxazole (SXT) and apramycin and/or streptomycin (AMINO).